The rate of drug related serious adverse events of therapeutic significance was calculated using ten RCTs involving 7,526 participants (4253 sGC modulators and 3273 placebo), that included ventricular tachycardia, cardiac failure, syncope, peripheral edema, pulmonary edema, hypotension, decreased cardiac output, headache, and pulmonary hemorrhage. This evidence concerns the gene SGCB and heart failure.